EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China

Qinglin Hu, Yuan Yang, Chen Yang, Miao Chen, Bing Han

Acta Haematologica · 2024

DOI: 10.1159/000539905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Qinglin Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China,…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Hydrazines, Pyrazoles, Benzoates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Aplastic anemia (AA) is characterized by bone marrow failure and cytopenia. Eltrombopag (ELT) is effective and safe for treating refractory/relapsed AA; however, reports on the long-term outcomes of transfusion-dependent non-severe AA (TD-NSAA) are limited.

Methods

Patients with TD-NSAA refractory to immunosuppressive therapy (IST) or relapsed after IST, treated with ELT alone, and followed up for at least 12 months were retrospectively enrolled. The baseline characteristics of patients, efficacy and adverse effects of ELT, and relapse and clone evolution rates after ELT were documented.

Results

Of the 55 patients with TD-NSAA included, 24 (43.6%) were men. Median age at diagnosis was 46 (19–80) years. Twenty-four patients had relapsed TD-NSAA, and 31 patients had refractory TD-NSAA. During the median follow-up period of 28 (12–48) months, the overall and complete response rates at 3, 6, and 12 months of ELT treatment were 38.2, 60.0, and 52.7 and 9.1, 14.6, and 9.1%, respectively. After a median follow-up of 28 (12–48) months, 21.2% (7/33) of patients experienced relapse, with a median duration from ELT treatment to relapse of 14 (6–45) months.

Conclusion

ELT was effective in patients with relapsed/refractory TD-NSAA, with tolerable adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, AplasticHydrazinesPyrazolesBenzoatesCyclosporineHumansMaleFemaleMiddle AgedAdultAgedFollow-Up StudiesAged, 80 and overChinaRetrospective StudiesRecurrenceTreatment OutcomeBlood TransfusionYoung AdultImmunosuppressive Agents

Stichwörter der Autor:innen

EltrombopagLong-term follow-upRefractoryRelapseTransfusion-dependent non-severe aplastic anemia

Substanzen

eltrombopagHydrazinesPyrazolesBenzoatesCyclosporineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, hqlin2012@163.com.
  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Zitieren

APA

Hu, Q., Yang, Y., Yang, C., Chen, M., & Han, B. (2024). Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China. Acta Haematologica. https://doi.org/10.1159/000539905

Vancouver

Hu Q, Yang Y, Yang C, Chen M, Han B. Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China. Acta Haematologica. 2024. doi:10.1159/000539905

BibTeX
@article{Hu2024,
  author = {Hu, Qinglin and Yang, Yuan and Yang, Chen and Chen, Miao and Han, Bing},
  title = {Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000539905}
}
Kostenlos starten →